AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML)... by Daver, N, Vyas, P, Kambhampati, S, Malki, MA, Larson, R, Asch, A, Mannis, G, Chai-Ho, W, Tanaka, T, Bradley, T, Jeyakumar, D, Wang, E, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, J, Sallman, D

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, G, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Sweet, K, Kantarjian, HM, Garcia-Manero, G, Komrokji, R, Xing, G, Ramsingh, G, Renard, C, Zeidner, JF, Sallman, DA

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results by Sallman, D, Asch, A, Kambhampati, S, Al Malki, M, Zeidner, J, Donnellan, W, Lee, D, Vyas, P, Jeyakumar, D, Mannis, G, Tanaka, T, Chai-Ho, W, Larson, R, Whiteley, A, Marcucci, G, Komrokji, R, Garcia-Manero, G, Van Elk, J, Lin, M, Maute, R, Volkmer, J-P, Takimoto, C, Chao, M, Daver, N